Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The deal will not be finalized until approved by Exact Sciences’ shareholders. With it, Abbott gains control of new diagnostic tools, including a popular at-home test for colorectal cancer.
Scott Gottlieb, MD, will take on the new position “effective immediately.” UnitedHealth Group did not say what, if any, steering committee the former FDA lead will sit on.
Dubbed “Clearity,” the new health plans will have four tiers to choose from, allowing patients to select the provider and services that are right for them. The insurance is similar to a concierge care model, but backed by a potentially larger network.
Krista Nelson made the official announcement on LinkedIn. She replaces Patrick Conway, MD, CEO of the broader Optum, who had held dual roles. Nelson has been with UnitedHealthcare since 2017.
A global tech and pharma supplier that introduced a generic equivalent to GE Healthcare’s Visipaque during the height of the 2022 contrast shortage has begun offering a substitute for Guerbet’s Dotarem.
An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.
The criminal saga of the X-ray business owner who got caught fleecing CMS of $2 million—while grabbing for another $1.7 million or so—has reached its epilogue.
Butterfly Network, Mindray and Philips introduced new point-of-care ultrasound offerings at ACEP 2022, the annual scientific assembly of the American College of Emergency Physicians.
GE Healthcare may ship its deep learning-based image reconstruction software called AIR Recon DL with new 3D capabilities, the company announced Sept. 29.
An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.
Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness.